Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: Results from the PRACMA study
Số trang: 10
Loại file: pdf
Dung lượng: 1,002.60 KB
Lượt xem: 6
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Macitentan is a dual endothelin receptor antagonist indicated for the long-term treatment of pulmonary arterial hypertension (PAH). We evaluated the change over time in REVEAL risk score in incident and prevalent patients receiving macitentan for the first time.
Nội dung trích xuất từ tài liệu:
Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: Results from the PRACMA study
Nội dung trích xuất từ tài liệu:
Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: Results from the PRACMA study
Tìm kiếm theo từ khóa liên quan:
BMC Pulmonary Medicine Observational study Pulmonary arterial hypertension Risk assessment Macitentan significantlyGợi ý tài liệu liên quan:
-
Ebook Genetics in medicine (8/E): Part 2
315 trang 28 0 0 -
The profile of older adults seeking chiropractic care: A secondary analysis
12 trang 27 0 0 -
Ebook Controlling salmonella in poultry production and processing: Part 1
132 trang 24 0 0 -
Paper F8: Audit and Assurance - Study text 2016
506 trang 24 0 0 -
Lecture Accounting information systems: Chapter 10 - Richardson, Chang, Smith
21 trang 23 0 0 -
Ebook Bovine viral diarrhea virus - Diagnosis, management, and control: Part 1
108 trang 21 0 0 -
Working in Health and Social Care
216 trang 20 0 0 -
Ebook Veterinary clinical epidemiology - From patient to population (4/E): Part 1
157 trang 19 0 0 -
Ebook Project management in the oil and gas industry: Part 2
177 trang 17 0 0 -
Efect of periodontal therapy on COPD outcomes: A systematic review
16 trang 16 0 0